336 related articles for article (PubMed ID: 21960059)
21. p53-dependent activation of microRNA-34a in response to etoposide-induced DNA damage in osteosarcoma cell lines not impaired by dominant negative p53 expression.
Novello C; Pazzaglia L; Conti A; Quattrini I; Pollino S; Perego P; Picci P; Benassi MS
PLoS One; 2014; 9(12):e114757. PubMed ID: 25490093
[TBL] [Abstract][Full Text] [Related]
22. Small molecule inhibition of Ewing sarcoma cell growth via targeting the long non coding RNA HULC.
Mercatelli N; Fortini D; Palombo R; Paronetto MP
Cancer Lett; 2020 Jan; 469():111-123. PubMed ID: 31639426
[TBL] [Abstract][Full Text] [Related]
23. Differential microRNA-34a expression and tumor suppressor function in retinoblastoma cells.
Dalgard CL; Gonzalez M; deNiro JE; O'Brien JM
Invest Ophthalmol Vis Sci; 2009 Oct; 50(10):4542-51. PubMed ID: 19443717
[TBL] [Abstract][Full Text] [Related]
24. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone.
Grier HE; Krailo MD; Tarbell NJ; Link MP; Fryer CJ; Pritchard DJ; Gebhardt MC; Dickman PS; Perlman EJ; Meyers PA; Donaldson SS; Moore S; Rausen AR; Vietti TJ; Miser JS
N Engl J Med; 2003 Feb; 348(8):694-701. PubMed ID: 12594313
[TBL] [Abstract][Full Text] [Related]
25. The over-expression of miR-34a fails to block DoHH2 lymphoma cell proliferation by reducing p53 via c-MYC down-regulation.
Rizzo M; Mariani L; Cavallini S; Simili M; Rainaldi G
Nucleic Acid Ther; 2012 Aug; 22(4):283-8. PubMed ID: 22830357
[TBL] [Abstract][Full Text] [Related]
26. miR-34a is an intracellular and exosomal predictive biomarker for response to docetaxel with clinical relevance to prostate cancer progression.
Corcoran C; Rani S; O'Driscoll L
Prostate; 2014 Sep; 74(13):1320-34. PubMed ID: 25053345
[TBL] [Abstract][Full Text] [Related]
27. GSTM4 is a microsatellite-containing EWS/FLI target involved in Ewing's sarcoma oncogenesis and therapeutic resistance.
Luo W; Gangwal K; Sankar S; Boucher KM; Thomas D; Lessnick SL
Oncogene; 2009 Nov; 28(46):4126-32. PubMed ID: 19718047
[TBL] [Abstract][Full Text] [Related]
28. RT-PCR evaluation of peripheral blood, bone marrow and peripheral blood stem cells in children and adolescents undergoing VACIME chemotherapy for Ewing's sarcoma and alveolar rhabdomyosarcoma.
Thomson B; Hawkins D; Felgenhauer J; Radich J
Bone Marrow Transplant; 1999 Sep; 24(5):527-33. PubMed ID: 10482938
[TBL] [Abstract][Full Text] [Related]
29. Reverse chemomodulatory effects of the SIRT1 activators resveratrol and SRT1720 in Ewing's sarcoma cells: resveratrol suppresses and SRT1720 enhances etoposide- and vincristine-induced anticancer activity.
Sonnemann J; Kahl M; Siranjeevi PM; Blumrich A; Blümel L; Becker S; Wittig S; Winkler R; Krämer OH; Beck JF
J Cancer Res Clin Oncol; 2016 Jan; 142(1):17-26. PubMed ID: 26055805
[TBL] [Abstract][Full Text] [Related]
30. Tumor suppressive microRNAs miR-34a/c control cancer cell expression of ULBP2, a stress-induced ligand of the natural killer cell receptor NKG2D.
Heinemann A; Zhao F; Pechlivanis S; Eberle J; Steinle A; Diederichs S; Schadendorf D; Paschen A
Cancer Res; 2012 Jan; 72(2):460-71. PubMed ID: 22102694
[TBL] [Abstract][Full Text] [Related]
31. [Primitive cutaneous Ewing's sarcoma: a diagnostic and therapeutic dilemma].
Delaplace M; Mélard P; Perrinaud A; Goré C; Vergier B; Machet L
Ann Dermatol Venereol; 2011 May; 138(5):395-8. PubMed ID: 21570564
[TBL] [Abstract][Full Text] [Related]
32. Biological indicators of prognosis in Ewing's sarcoma: an emerging role for lectin galactoside-binding soluble 3 binding protein (LGALS3BP).
Zambelli D; Zuntini M; Nardi F; Manara MC; Serra M; Landuzzi L; Lollini PL; Ferrari S; Alberghini M; Llombart-Bosch A; Piccolo E; Iacobelli S; Picci P; Scotlandi K
Int J Cancer; 2010 Jan; 126(1):41-52. PubMed ID: 19544526
[TBL] [Abstract][Full Text] [Related]
33. CD99 triggering in Ewing sarcoma delivers a lethal signal through p53 pathway reactivation and cooperates with doxorubicin.
Guerzoni C; Fiori V; Terracciano M; Manara MC; Moricoli D; Pasello M; Sciandra M; Nicoletti G; Gellini M; Dominici S; Chiodoni C; Fornasari PM; Lollini PL; Colombo MP; Picci P; Cianfriglia M; Magnani M; Scotlandi K
Clin Cancer Res; 2015 Jan; 21(1):146-56. PubMed ID: 25501132
[TBL] [Abstract][Full Text] [Related]
34. Tissue microRNA-126 expression level predicts outcome in human osteosarcoma.
Liu W; Zhao ZY; Shi L; Yuan WD
Diagn Pathol; 2015 Jul; 10():116. PubMed ID: 26194657
[TBL] [Abstract][Full Text] [Related]
35. miRNA-34a is associated with docetaxel resistance in human breast cancer cells.
Kastl L; Brown I; Schofield AC
Breast Cancer Res Treat; 2012 Jan; 131(2):445-54. PubMed ID: 21399894
[TBL] [Abstract][Full Text] [Related]
36. Overcoming resistance to conventional drugs in Ewing sarcoma and identification of molecular predictors of outcome.
Scotlandi K; Remondini D; Castellani G; Manara MC; Nardi F; Cantiani L; Francesconi M; Mercuri M; Caccuri AM; Serra M; Knuutila S; Picci P
J Clin Oncol; 2009 May; 27(13):2209-16. PubMed ID: 19307502
[TBL] [Abstract][Full Text] [Related]
37. Prognostic and therapeutic relevance of HER2 expression in osteosarcoma and Ewing's sarcoma.
Scotlandi K; Manara MC; Hattinger CM; Benini S; Perdichizzi S; Pasello M; Bacci G; Zanella L; Bertoni F; Picci P; Serra M
Eur J Cancer; 2005 Jun; 41(9):1349-61. PubMed ID: 15913990
[TBL] [Abstract][Full Text] [Related]
38. Cyclin D1 and Ewing's sarcoma/PNET: A microarray analysis.
Fagone P; Nicoletti F; Salvatorelli L; Musumeci G; Magro G
Acta Histochem; 2015 Oct; 117(8):824-8. PubMed ID: 26363896
[TBL] [Abstract][Full Text] [Related]
39. Prognostic factors and patterns of relapse in ewing sarcoma patients treated with chemotherapy and r0 resection.
Pan HY; Morani A; Wang WL; Hess KR; Paulino AC; Ludwig JA; Lin PP; Daw NC; Mahajan A
Int J Radiat Oncol Biol Phys; 2015 Jun; 92(2):349-57. PubMed ID: 25772182
[TBL] [Abstract][Full Text] [Related]
40. Interferon-gamma sensitizes resistant Ewing's sarcoma cells to tumor necrosis factor apoptosis-inducing ligand-induced apoptosis by up-regulation of caspase-8 without altering chemosensitivity.
Lissat A; Vraetz T; Tsokos M; Klein R; Braun M; Koutelia N; Fisch P; Romero ME; Long L; Noellke P; Mackall CL; Niemeyer CM; Kontny U
Am J Pathol; 2007 Jun; 170(6):1917-30. PubMed ID: 17525260
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]